- Home
- LASR vs VKTX Comparison
LASR vs VKTX Comparison
Compare LASR & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LASR | VKTX |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LASR | VKTX |
|---|---|---|
| Price | $69.44 | $39.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $54.31 | ★ $95.86 |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.99 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $191,359,000.00 | N/A |
| Revenue This Year | $10.91 | N/A |
| Revenue Next Year | $14.32 | N/A |
| P/E Ratio | $6,504.00 | ★ N/A |
| Revenue Growth | ★ 38.09 | N/A |
| 52 Week Low | $17.84 | $22.96 |
| 52 Week High | $86.95 | $43.15 |
Technical Indicators
Market Signals| Indicator | LASR | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 76.91 |
| Support Level | $62.28 | $28.50 |
| Resistance Level | $72.04 | $39.78 |
| Average True Range (ATR) | 4.78 | 2.03 |
| MACD | 0.08 | 1.16 |
| Stochastic Oscillator | 76.96 | 87.94 |
Price Performance
Historical ComparisonAbout LASR nLIGHT Inc.
nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products segment, which includes semiconductor lasers, fiber lasers, and directed energy products; and Advanced Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA, of which maximum revenue is derived from North America.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.